Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc
Public
Traded as NASDAQ: PPHM,NASDAQ: PPHMP
Industry Pharmaceuticals
Founded 1981
Headquarters Tustin, California, United States
Key people
 Steven W. King
(President and CEO)
Products Drugs
Revenue Increase US$ 22.401 million (2014)[1]
Increase US$ -35.706 million (2014)[1]
Increase US$ -35.362 million (2014)[1]
Total assets Increase US$ 90.545 million (2014)[1]
Total equity Increase US$ 90.545 million (2014)[1]
Number of employees
 180 (April 30, 2014)[1]
Website www.peregrineinc.com

Peregrine Pharmaceuticals, Inc. is an American biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. Peregrine is pursuing multiple clinical programs in cancer with their lead immunotherapy product candidate bavituximab, PET imaging agent 124I-PGN650, and brain cancer agent Cotara. Peregrine also has in-house cGMP manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and biomanufacturing services for both Peregrine and outside customers.[2]

History

Peregrine was founded in June 3, 1981 under its former name Techniclone International Corporation, a California corporation. On March 24, 1997, Techniclone International Corporation was merged with and into Techniclone Corporation, a corporation incorporated in the State of Delaware on September 25, 1996. This merger was effected for the purpose of effecting a change in the Company's state of incorporation from California to Delaware. The Company changed its name from Techniclone Corporation to Peregrine Pharmaceuticals, Inc. in October 2000.[3]

Clinical trials

Phase III

The SUNRISE trial is an ongoing international clinical trial studying non-small-cell lung carcinoma (NSCLC). It was started in December 2013 and is projected to end in December 2016.

The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.[4] Bavituximab has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of second-line non-small cell lung cancer (NSCLC).[5]

In a Phase 2 clinical trial, in patients who mirror the entry criteria for the SUNRISE trial, the 3 mg/kg bavituximab plus docetaxel arm resulted in a median overall survival of 11.7 months compared to 7.3 months in the control arm with the 3 mg/kg bavituximab plus docetaxel combination arm being well-tolerated with no significant differences in adverse events between the trial arms.[6]

Phase I and II

Bavituximab is currently being evaluated in several solid tumor indications, including non-small cell lung cancer, breast cancer, liver cancer, rectal cancer and advanced melanoma.[7][8]

Imaging study

PET imaging agent 124I-PGN650 is being evaluated in a tumor imaging and dosimetry study.[9]

See also

Notes and references